Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > How does Accelerated Approval work

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Nov 19, 2024 2:45pm

52 Views

Post# 36320303

RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

Not even the restrictions outlined by Professor Heineken..? Like the FACT they need 18 months to recruit and treat 180 patients, and 6 months of follow up to gather statisically relevant data for application for accelerated approval.

If ONCY were able to apply for AA at any time... then they would be doing exactly that, RIGHT NOW. Y

Not even your lies can correct the trajectory of this tired old dog of a company... The sooner they fold the better, then you can move on and get a life.

still, pps is only down 97% since inception. Load up folks... to da moon...!!

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3